Fax: (508) 793-6110
Oncofetal protein IMP3
A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas
Article first published online: 15 APR 2008
Copyright © 2008 American Cancer Society
Volume 112, Issue 12, pages 2676–2682, 15 June 2008
How to Cite
Jiang, Z., Lohse, C. M., Chu, P. G., Wu, C.-L., Woda, B. A., Rock, K. L. and Kwon, E. D. (2008), Oncofetal protein IMP3. Cancer, 112: 2676–2682. doi: 10.1002/cncr.23484
- Issue published online: 4 JUN 2008
- Article first published online: 15 APR 2008
- Manuscript Accepted: 17 DEC 2007
- Manuscript Revised: 11 DEC 2007
- Manuscript Received: 6 NOV 2007
- oncofetal protein;
- mRNA binding protein;
- prognostic biomarker;
- papillary renal cell carcinoma;
- chromophobe renal cell carcinoma
Whether an oncofetal protein, IMP3, can serve as a prognostic biomarker to predict metastasis for patients with localized papillary and chromophobe subtypes of renal cell carcinomas (RCCs) was investigated.
The expression of IMP3 in 334 patients with primary papillary and chromophobe RCC from multiple medical centers was evaluated by immunohistochemistry. The 317 patients with localized papillary and chromophobe RCCs were further evaluated for outcome analyses.
IMP3 was significantly increased in a subset of localized papillary and chromophobe RCCs that subsequently metastasized. Patients with localized IMP3-positive tumors (n = 33; 10%) were over 10 times more likely to metastasize (risk ratio [RR], 11.38; 95% confidence interval [CI], 5.40-23.96; P < .001) and were nearly twice as likely to die (RR, 1.91; 95% CI, 1.13–3.22; P = .016) compared with patients with localized IMP3 negative tumors. The 5-year metastasis-free and overall survival rates were 64% and 58% for patients with IMP3-positive localized papillary and chromophobe RCCs compared with 98% and 85% for patients with IMP3 negative tumors, respectively. In multivariable analysis adjusting for the TNM stage and nuclear grade, patients with IMP3-positive tumors were still over 10 times more likely to progress to distant metastasis (RR, 13.45; 95% CI, 6.00–30.14; P < .001) and were still nearly twice as likely die (RR, 1.95; 95% CI, 1.15–3.31; P = .013) compared with patients with IMP3-negative tumors.
IMP3 is an independent prognostic biomarker that can be used to identify a subgroup of patients with localized papillary and chromophobe RCC who are at high risk for developing distant metastasis. Cancer 2008. © 2008 American Cancer Society.